Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|March 15, 2017
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trialEvan W Alley, Juanita Lopez, Armando Santoro, et al.
Movement Disorders Clinical Practice|November 7, 2022
A Placebo-Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's DiseaseEva Thijssen, Soma Makai-Bölöni, Emilie van Brummelen, et al.
JMIR Formative Research|September 13, 2022
Objective Monitoring of Facioscapulohumeral Dystrophy During Clinical Trials Using a Smartphone App and Wearables: Observational StudyGhobad Maleki, Ahnjili Zhuparris, Ingrid Koopmans, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 15, 2022
A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide VaccineHui Jing Yu, Eva Thijssen, Emilie van Brummelen, et al.
JMIR Formative Research|March 15, 2023
Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional StudyAhnjili Zhuparris, Ghobad Maleki, Ingrid Koopmans, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 20, 2022
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009Eva Thijssen, Jonas den Heijer, David Puibert, et al.
Cancer Chemotherapy and Pharmacology|March 16, 2018
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAKEmma Dean, Udai Banerji, Jan H M Schellens, et al.
Journal of Parkinson'S Disease|August 30, 2024
Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's DiseasePepijn P N M Eijsvogel, Laura G J M Borghans, Samantha Prins, et al.
Blood Advances|June 3, 2026
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSSonja Zweegman, Thierry Facon, Vania Hungria, et al.
Pageof 1